Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
September 03, 2020 17:00 ET | Source: ObsEva SA

ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million

GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing...
August 07, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020

Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
August 06, 2020 01:00 ET | Source: ObsEva SA

ObsEva Announces Second Quarter 2020 Financial Results and Business Update

Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids Phase 3 data from PRIMROSE 2 trial demonstrated...
July 15, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020

Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
July 06, 2020 01:00 ET | Source: ObsEva SA

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and...
July 03, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
July 01, 2020 01:00 ET | Source: ObsEva SA

ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA

Geneva, Switzerland and Boston, MA – July 1, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
June 29, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids

Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
June 09, 2020 16:01 ET | Source: ObsEva SA

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020

Geneva, Switzerland and Boston, MA – June 9, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...